174422-22-1

Basic information

• Product Name: Benzoic acid, 4-[[(4-chlorophenyl)methyl]amino]-3-nitro-, methyl ester
• Synonyms: methyl 4-(p-chlorobenzylamino)-3-nitro-benzoate;4-(4-Chloro-benzylamino)-3-nitro-benzoic acid methyl ester;methyl 4-((4-chlorobenzyl)amino)-3-nitrobenzoate;methyl 4-{[(4-chlorophenyl)methyl]amino}-3-nitrobenzoate
• CAS NO: 174422-22-1
• Molecular Formula: C15H13ClN2O4
• Molecular Weight: 320.732
• Mol File: 174422-22-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 142 °C
• CAS DataBase Reference: Benzoic acid, 4-[[(4-chlorophenyl)methyl]amino]-3-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[[(4-chlorophenyl)methyl]amino]-3-nitro-, methyl ester(174422-22-1)
• EPA Substance Registry System: Benzoic acid, 4-[[(4-chlorophenyl)methyl]amino]-3-nitro-, methyl ester(174422-22-1)

Safety Data

• Hazardous Substances Data: 174422-22-1(Hazardous Substances Data)

Upstream product

• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 104-86-9 4-chlorobenzylamine 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 96-99-1 4-chloro-3-nitrobenzoate 

Downstream Products

• 1168139-12-5 methyl 1-[(4-chlorophenyl)methyl]-2-methyl-1H-benzimidazole-5-carboxylate 
• 1096969-16-2 1-[(4-chlorophenyl)methyl]-2-methyl-1H-benzimidazole-5-carboxylic acid 
• 1168138-16-6 1-[(4-chlorophenyl)methyl]-2-methyl-N-[(1R)-1-phenylpropyl]-1H-benzimidazole-5-carboxamide 
• 848819-92-1 1-(4-chloro-benzyl)-2-ethoxycarbonylmethyl-1H-benzoimidazole-5-carboxylic acid methyl ester 
• 174422-23-2 methyl 3-amino-4-(p-chlorobenzylamino)benzoate 
• 1168139-13-6 methyl 1-(4-chlorobenzyl)-1H-benzo[d]imidazole-5-carboxylate 
• 1438983-62-0 (S)-1-(4-chlorobenzyl)-N-(1-(3-isopropylphenyl)ethyl)-1H-benzo[d]imidazole-5-carboxamide 
• 1036539-29-3 1-(4-chlorobenzyl)-1H-benzo[d]imidazole-5-carboxylic acid 
• 174422-21-0 1-(4-Chloro-benzyl)-2-(2,4-dichloro-phenyl)-1H-benzoimidazole-5-carboxylic acid 
• 174422-20-9 1-(4-Chloro-benzyl)-2-(4-chloro-phenyl)-1H-benzoimidazole-5-carboxylic acid 
• 214903-74-9 1-(4-Chloro-benzyl)-2-(4-methyl-piperazin-1-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester 
• 214903-76-1 1-(4-Chloro-benzyl)-2-(4-methyl-piperazin-1-yl)-1H-benzoimidazole-5-carboxylic acid 

Relevant articles and documents

3D-Printed Polypropylene Continuous-Flow Column Reactors: Exploration of Reactor Utility in SNAr Reactions and the Synthesis of Bicyclic and Tetracyclic Heterocycles

3D printing has the potential to transform the way in which chemical reactions are carried out due to its low-cost, ease-of-use as a technology and its capacity to expedite the development of iteratively enhanced prototypes. In this present study, we developed a novel, low-cost polypropylene (PP) column reactor that was incorporated into an existing continuous-flow reactor for the synthesis of heterocycles. The utility and solvent resistance of the printed devices were explored in SNAr reactions to produce substituted aniline derivatives and in the synthesis of bicyclic and tetracyclic heterocycles. Using this approach, a range of heterocyclic compounds was synthesised including the core structure of the natural product (±)-γ-lycorane and structurally complex compounds based on the tetracyclic core of the erythrina alkaloids.

NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compoun

Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist

The peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated nuclear receptor, thought to play a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. A novel benzimidazole series of centrally penetrant PPARγ partial agonists has been identified. The optimization of PPARγ activity and in vivo pharmacokinetics leading to the identification of GSK1997132B a potent, metabolically stable and centrally penetrant PPARγ partial agonist, is described.